European ancestry increases breast cancer risk among Latinas EurekAlert (press release), DC - PHILADELPHIA ? Latina women have a lower risk of breast cancer than European or African-American women generally, but those with higher European ancestry ...
Health Buzz: New Flu Vaccines and Other Health News U.S. News & World Report, DC - While much attention is paid to breast cancer diagnosis and treatment, a side effect that is rarely discussed is how tough it is for breast cancer patients ...
Perceived Discrimination Affects Screening Rates Science Daily (press release) - If detected early, five-year survival rates for colorectal and breast cancer are approximately 90 percent. However, if caught in later stages, the survival ...
Prostate cancer rate spurs campaigners So Md News, MD - The county health department in White Plains offers prostate, colorectal, cervical and breast cancer screenings, said Chinnadurai Devadason, the county?s ...
Developmental effects of endocrine-disrupting chemicals in wildlife and humans - T Colborn, FS Vom Saal, AM Soto - Environmental Health Perspectives, 1993 - Mass Med Soc ... The authors suggest that longer cycles may reduce breastcancer risk by reducing ...
Published in Journal Watch Women's Health November 1, 1996. Citation(s): ...
Lymphatic mapping and sentinel lymphadenectomy for breast cancer. - AE Giuliano, DM Kirgan, JM Guenther, DL Morton - Annals of Surgery, 1994 - pubmedcentral.nih.gov ... at Saint John's Hospital and Health Center, Santa ... lymph node dissection (ALND) for breastcancer generally is ... node sampling or level I dissection may miss some ...
… Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior … - … , M Ellis, S Come, SZ Gertler, JT May, G Burton, I … - Journal of Clinical Oncology, 2002 - jco.ascopubs.org ... Center, Washington, DC; Ottawa Regional Cancer Center, Ottawa ... VA; Louisiana State
University Health Science Center ... to CK Osborne, MD, Breast Center, Baylor ...
… Postmenopausal Women. Principal Results From the Women's Health Initiative Randomized Controlled … - JE Rossouw, GL Anderson, RL Prentice, AZ LaCroix, … - Journal of the American Medical Association, 2002 - escholarship.umassmed.edu ... progestin component of the Women's Health Initiative, a ... CHD death), with invasive breastcancer as the ... PE), endometrial cancer, colorectal cancer, hip fracture ...
Effective physician-patient communication and health outcomes: a review - MA Stewart - Canadian Medical Association Journal, 1995 - Can Med Assoc ... and Their Parents in Pediatric Health Care Settings ... PM Ravdin Decreased Use of Adjuvant BreastCancer Therapy in a ... Risk Information Med Decis Making, May 1, 2005 ...
Breast Cancer in Younger Women: Reproductive and Late Health Effects of Treatment - PA Ganz, GA Greendale, L Petersen, B Kahn, JE … - Journal of Clinical Oncology, 2003 - jco.ascopubs.org ... Conclusion: Overall QOL in younger women who survive breastcancer is good, but
there is ... Factors that may contribute to poorer health perceptions and QOL ...
Environmental and dietary estrogens and human health: Is there a problem? - SH Safe - Environmental Health Perspectives, 1995 - pubmedcentral.nih.gov ... 1993 May 29;341(8857):1392?1395. ... T, Hoel DG, Anton-Culver H. Medical hypothesis:
xenoestrogens as preventable causes of breastcancer. Environ Health Perspect ...
Breast-cancer drug may increase other health risks
Women with heart disease or a high risk for it would trade one set of odds for another if they took the drug raloxifene to try to prevent breast cancer, a study suggests.
The drug helped prevent cancer but raised the risk of blood clots and fatal strokes. It also didn't lower the risk of death, hospitalization or heart attack, as some had hoped it would.
Doctors have been testing raloxifene as an alternative to tamoxifen for preventing breast cancer and as a way to lower heart-disease risks.
Based on the new study's results, "most people would decline taking raloxifene" unless they have a high risk of breast cancer, said Dr. Linda Vahdat, director of breast-cancer research at Weill Cornell Medical College.
Dr. Marisa Weiss agreed. The Philadelphia breast-cancer specialist founded the consumer Web site breastcancer.org.
"The cardiac benefit wasn't there. The side effects were," and breast cancer is more treatable than life-threatening blood clots and strokes, she said.
Neither doctor took part in the study, which involved 10,101 postmenopausal women in the United States and 25 other countries. Results were to be published in today's New England Journal of Medicine.
Many of the authors consult or work for Indianapolis-based Eli Lilly & Co., which makes raloxifene and paid for the study. The drug is sold as Evista for treating the bone disease osteoporosis, but the company is seeking approval to market it for breast-cancer prevention.
A similar drug, tamoxifen, has long been used to prevent breast cancers whose growth is fueled by the hormone estrogen.
